Eli Lilly and Company (NYSE:LLY) Shares Up 0.1% on Analyst Upgrade

Eli Lilly and Company (NYSE:LLY)’s stock price was up 0.1% on Monday after Citigroup raised their price target on the stock from $1,060.00 to $1,250.00. Citigroup currently has a buy rating on the stock. Eli Lilly and Company traded as high as $895.88 and last traded at $893.64. Approximately 576,701 shares traded hands during trading, a decline of 80% from the average daily volume of 2,947,208 shares. The stock had previously closed at $892.70.

A number of other equities analysts also recently weighed in on the stock. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Guggenheim lifted their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,013.41.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Nikulski Financial Inc. boosted its position in shares of Eli Lilly and Company by 39.7% during the 3rd quarter. Nikulski Financial Inc. now owns 2,869 shares of the company’s stock valued at $2,542,000 after acquiring an additional 816 shares during the last quarter. HM Payson & Co. raised its stake in Eli Lilly and Company by 1.8% in the third quarter. HM Payson & Co. now owns 21,953 shares of the company’s stock valued at $19,449,000 after purchasing an additional 378 shares in the last quarter. Catalyst Financial Partners LLC lifted its position in Eli Lilly and Company by 3.6% during the third quarter. Catalyst Financial Partners LLC now owns 4,842 shares of the company’s stock valued at $4,290,000 after purchasing an additional 166 shares during the last quarter. Tevis Investment Management grew its stake in Eli Lilly and Company by 3.2% in the 3rd quarter. Tevis Investment Management now owns 925 shares of the company’s stock worth $820,000 after buying an additional 29 shares in the last quarter. Finally, Goldstone Financial Group LLC purchased a new position in Eli Lilly and Company in the 3rd quarter worth approximately $260,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.0 %

The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock has a market cap of $848.59 billion, a P/E ratio of 131.61, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The stock’s fifty day moving average price is $919.74 and its 200 day moving average price is $863.20.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts forecast that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.